RayzeBio

RayzeBio

featured image of BMS Expands Oncology Portfolio with $41bn RayzeBio Acquisition

BMS Expands Oncology Portfolio with $41bn RayzeBio Acquisition

BIOT

💼 Bristol Myers Squibb (BMS) acquires RayzeBio for $4.1bn, expanding its oncology portfolio with targeted radiopharmaceuticals. ⚕️🎯